Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomised phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.

CONCLUSIONS: Tildrakizumab was well-tolerated and efficacy was well-maintained in week 28 responders who continued tildrakizumab treatment through three years or improved among etanercept partial responders/non-responders who switched to tildrakizumab. This article is protected by copyright. All rights reserved.
PMID: 31218661 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - June 18, 2019 Category: Dermatology Authors: Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D Tags: Br J Dermatol Source Type: research